BNT162b2 vaccine effectiveness in chronic kidney disease patients-an observational study.

Bielopolski, Dana; Libresco, Gilad; Barda, Noam; Dagan, Noa; Steinmetz, Tali; Yahav, Dafna; Charytan, David M; Balicer, Ran D; Rozen-Zvi, Benaya

Bielopolski, Dana; Libresco, Gilad; Barda, Noam; Dagan, Noa; Steinmetz, Tali; Yahav, Dafna; Charytan, David M; Balicer, Ran D; Rozen-Zvi, Benaya.

Afiliación

Bielopolski D; Department of Nephrology and Hypertension, Rabin Medical Center, Petah-Tikva, Israel.
Libresco G; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Barda N; Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel.
Dagan N; ARC Innovation Center, Sheba Medical Center, Ramat-Gan, Israel.
Steinmetz T; Department of Software and Information Systems Engineering, Ben Gurion University, Be'er Sheva, Israel.
Yahav D; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
Charytan DM; Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel.
Balicer RD; Department of Software and Information Systems Engineering, Ben Gurion University, Be'er Sheva, Israel.
Rozen-Zvi B; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.

Clin Kidney J ; 15(10): 1838-1846, 2022 Oct.

Article en En | MEDLINE | ID: mdl-36147707

Palabras clave

BNT162b2 vaccine; COVID-19; chronic kidney disease

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: Clin Kidney J Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google